2012
DOI: 10.3111/13696998.2012.675380 View full text |Buy / Rent full text
|
|

Abstract: Denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
73
1
4

Publication Types

Select...

Relationship

0
0

Authors

Journals